A Target Antigen-Based Approach to the Classification of Membranous Nephropathy.
Sign Up to like & getrecommendations! Published in 2021 at "Mayo Clinic proceedings"
DOI: 10.1016/j.mayocp.2020.11.028
Abstract: OBJECTIVE To describe the clinical and pathological phenotype of membranous nephropathy (MN) associated with M-type-phospholipase-A2-receptor (PLA2R), thrombospondin-type-1-domain-containing-7A (THSD7A), semaphorin 3B (SEMA3B), neural-epidermal-growth-factor-like-1-protein (NELL-1), protocadherin 7 (PCDH7), exostosin 1/exostosin 2 (EXT1/EXT2) and neural cell adhesion molecule… read more here.
Keywords: disease; target; membranous nephropathy; target antigen ... See more keywords
Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the American Society of Nephrology : JASN"
DOI: 10.1681/asn.2020101395
Abstract: BACKGROUND Identification of target antigens PLA2R, THSD7A, NELL1, or Semaphorin-3B can explain the majority of cases of primary membranous nephropathy (MN). However, target antigens remain unidentified in 15%-20% of patients. METHODS A multipronged approach, using… read more here.
Keywords: serine protease; target; htra1; protease htra1 ... See more keywords
Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15061845
Abstract: Simple Summary Antibody-Drug Conjugates (ADCs) provide effective anti-cancer treatments. ADC development requires the identification of appropriate tumour-associated antigens that can be targeted by the ADC to effectively kill cancer cells while minimising damage to healthy… read more here.
Keywords: clinically approved; drug conjugates; conjugates adcs; target antigen ... See more keywords